Under the six-tier approach for precision therapies proposed by Byrne and colleagues [145], mTOR inhibitors for the treatment of TSC-associated epilepsy and solid tumors fall within Tier 3, wherein the therapy directly targets gene dysfunction. The gene discussed is MTOR; the disease is epilepsy.